272 research outputs found
EP-2007: A multicenter study of exclusive brachytherapy in younger patients with prostate cancer
Real-time lossless compression of multibeam echosounder water column data
Multibeam echosounders can generate vast amounts of data when recording the complete water column, which poses logistic, economic and technical challenges. Lossy data compression can reduce data size up to one or two orders of magnitude, but often at the expense of significant image distortion. Lossless compression ratios tend to be modest and at a high computing cost. In this work we test a high-performance data compression algorithm, FAPEC, initially developed for Space data communications with low computing requirements. FAPEC provides good compression ratios and supports tailored pre-processing stages. Here we show its advantages over standard and high-end lossless compression solutions currently available, both in terms of ratios and speedR+D work on FAPEC is supported by the ESA Business Incubation Programme through Barcelona Activa, by the MINECO (Spanish Ministry of Economy) – FEDER through grants ESP2014-55996-C2-1-R, AYA2014-59084-P and MDM-2014-0369 of ICCUB (Unidad de Excelencia ‘María de Maeztu’), and by the AGAUR.
This project has received funding from the European Union’s Horizon 2020
research and innovation programme under the Marie Sklodowska-Curie grant
agreement No 658358 (D. Amblas). The authors acknowledge funding received from the Spanish RTD grant NUREIEV (CTM2013-44598-R) and from EC contract MIDAS (GA-603418). GRC Geociencies Marines is recognized by Generalitat de Catalunya as an excellence research group (ref. 2014 SGR 1068)
Protocol for the detection and nutritional management of high-output stomas
Introduction:
An issue of recent research interest is excessive stoma output and its relation to electrolyte abnormalities. Some studies have identified this as a precursor of dehydration and renal dysfunction. A prospective study was performed of the complications associated with high-output stomas, to identify their causes, consequences and management.Materials and methods:
This study was carried out by a multidisciplinary team of surgeons, gastroenterologists, nutritionists and hospital pharmacists. High-output stoma (HOS) was defined as output ≥1500 ml for two consecutive days. The subjects included in the study population, 43 patients with a new permanent or temporary stoma, were classified according to the time of HOS onset as early HOS (<3 weeks after initial surgery) or late HOS (≥3 weeks after surgery). Circumstances permitting, a specific protocol for response to HOS was applied. Each patient was followed up until the fourth month after surgery.Results:
Early HOS was observed in 7 (16 %) of the sample population of 43 hospital patients, and late HOS, in 6 of the 37 (16 %) non-early HOS population. By type of stoma, nearly all HOS cases affected ileostomy, rather than colostomy, patients. The patients with early HOS remained in hospital for 18 days post surgery, significantly longer than those with no HOS (12 days). The protocol was applied to the majority of EHOS patients and achieved 100 % effectiveness. 50 % of readmissions were due to altered electrolyte balance. Hypomagnesaemia was observed in 33 % of the late HOS patients.Conclusion:
The protocol developed at our hospital for the detection and management of HOS effectively addresses possible long-term complications arising from poor nutritional status and chronic electrolyte alteration
Moments of Inertia of Nuclei in the Rare Earth Region: A Relativistic versus Non-Relativistic Investigation
A parameter free investigation of the moments of inertia of ground state
rotational bands in well deformed rare-earth nuclei is carried out using
Cranked Relativistic Hartree-Bogoliubov (CRHB) and non-relativistic Cranked
Hartree-Fock-Bogoliubov (CHFB) theories. In CRHB theory, the relativistic
fields are determined by the non-linear Lagrangian with the NL1 force and the
pairing interaction by the central part of finite range Gogny D1S force. In
CHFB theory, the properties in particle-hole and particle-particle channels are
defined solely by Gogny D1S forces. Using an approximate particle number
projection before variation by means of the Lipkin Nogami method improves the
agreement with the experimental data, especially in CRHB theory. The effect of
the particle number projection on the moments of inertia and pairing energies
is larger in relativistic than in non-relativistic theory.Comment: 18 pages + 2 PostScript figure
Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcoma of the extremities
To analyze the patterns of failure and the toxicity profile of
intraoperative electron beam radiotherapy (IOERT) after resection of soft tissue
sarcomas of the extremities (STS). PATIENTS AND METHODS: Forty-five patients with
extremity STS were treated with IOERT and moderate-dose postoperative
radiotherapy (45-50 Gy). Twenty-six patients were treated for primary disease
(PD) and 19 patients for an isolated recurrence (ILR). Tumor size was >5 cm
(maximum diameter) in 36 patients (80%), and high-grade histology in PD patients
was present in 14 patients (54%). In nine patients, IOERT was used alone, due to
previous irradiation or patient refusal. Chemotherapy (neoadjuvant and/or
adjuvant) was mainly given to high-grade tumors. RESULTS: Nine patients relapsed
in the extremity (20%), and 12 patients in distant sites (28%). Actuarial local
control at 5 years was 88% for patients with negative/close margins and 57% for
patients presenting positive margins (P=0.04). Five patients (11%) developed
neuropathy associated with the treatment. Extremity preservation was achieved in
40 patients (88%). With a median follow-up of 93 months (range: 27-143 months)
for the patients at risk, 25 patients remain alive (a 7-year actuarial survival
rate of 75% for PD and 47% for ILR; P=0.01). CONCLUSIONS: IOERT combined with
moderate doses of external beam irradiation yields high local control and
extremity preservation rates in resected extremity STS. Peripheral nerves in the
IOERT field are dose-limiting structures requiring a dose compromise in the IOERT
component to avoid severe neurological damage
Cancer pharmacogenetics
The large number of active combination chemotherapy regimens for most cancers has led to the need for better information to guide the \u27standard\u27 treatment for each patient. In an attempt to individualise therapy, pharmacogenetics and pharmacogenomics (a polygenic approach to pharmacogenetic studies) encompass the search for answers to the hereditary basis for interindividual differences in drug response. This review will focus on the results of studies assessing the effects of polymorphisms in drug-metabolising enzymes and drug targets on the toxicity and response to commonly used chemotherapy drugs. In addition, the need for polygenic pharmacogenomic strategies to identify patients at risk for adverse drug reactions will be highlighted
The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma
The present study retrospectively examined the correlation between the outcome of patients with locally advanced oesophageal squamous cell carcinoma (cT3-4 cN0-1 cM0) after multimodal treatment (radiochemotherapy±surgical resection), and the presence of genetic polymorphisms in genes involved in folate metabolism. In total, 68 patients who took part in a prospective multicentric trial received 5-fluorouracil (FU)-based radiochemotherapy, optionally followed by surgery. DNA was extracted from pretherapeutic tumour biopsies and was subsequently genotyped for common genetic polymorphisms of three genes (MTHFR C677T, MTR A2756G, TS tandem repeat polymorphism) involved in folate metabolism and potentially in sensitivity to 5-FU-based chemotherapy. The genotypes were correlated with tumour response to polychemotherapy, radiochemotherapy and with overall survival. Tumours with the MTR wild-type genotype (2756AA) showed a median survival time of 16 months, whereas tumours with an MTR variant genotype (2756AG/2756GG) showed a median survival time of 42 months (P=0.0463). No prognostic impact could be verified for the genotypes of the MTHFR genes and the TS gene. Among tumours treated with radiochemotherapy and subsequent resection, MTR variant genotype showed higher histopathological response rate than tumours with MTR wild-type genotype (P=0.0442). In contrast, no significant relationship between clinically determined tumour regression after polychemotherapy and polymorphisms of the three genes under analysis was observed. In conclusion, pretherapeutic determination of the MTR A2756G polymorphism may predict survival of multimodally treated oesophageal squamous cell carcinomas. Determination of MTHFR C677T and TS tandem repeat polymorphism has no predictive value
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol
Alzheimer's disease (AD) is a conformational disease that is characterized by amyloid-β (Aβ) deposition in the brain. Aβ exerts its toxicity in part by receptor-mediated interactions that cause down-stream protein misfolding and aggregation, as well as mitochondrial dysfunction. Recent reports indicate that Aβ may also interact directly with intracellular proteins such as the mitochondrial enzyme ABAD (Aβ binding alcohol dehydrogenase) in executing its toxic effects. Mitochondrial dysfunction occurs early in AD, and Aβ's toxicity is in part mediated by inhibition of ABAD as shown previously with an ABAD decoy peptide. Here, we employed AG18051, a novel small ABAD-specific compound inhibitor, to investigate the role of ABAD in Aβ toxicity. Using SH-SY5Y neuroblastoma cells, we found that AG18051 partially blocked the Aβ-ABAD interaction in a pull-down assay while it also prevented the Aβ42-induced down-regulation of ABAD activity, as measured by levels of estradiol, a known hormone and product of ABAD activity. Furthermore, AG18051 is protective against Aβ42 toxicity, as measured by LDH release and MTT absorbance. Specifically, AG18051 reduced Aβ42-induced impairment of mitochondrial respiration and oxidative stress as shown by reduced ROS (reactive oxygen species) levels. Guided by our previous finding of shared aspects of the toxicity of Aβ and human amylin (HA), with the latter forming aggregates in Type 2 diabetes mellitus (T2DM) pancreas, we determined whether AG18051 would also confer protection from HA toxicity. We found that the inhibitor conferred only partial protection from HA toxicity indicating distinct pathomechanisms of the two amyloidogenic agents. Taken together, our results present the inhibition of ABAD by compounds such as AG18051 as a promising therapeutic strategy for the prevention and treatment of AD, and suggest levels of estradiol as a suitable read-out
- …